Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Fosmidomycin-piperaquine combo viable alternative to artemisinin for malaria

24 Jan 2018
Only certain species of mosquitoes of the Anopheles genus – and only females of those species – can transmit malaria.

The fosmidomycin-piperaquine combination therapy appears to have high clinical efficacy and acceptable safety for the treatment of uncomplicated Plasmodium falciparum malaria, and may thus be considered a viable artemisinin substitute, a recent study shows.

The study included both adult and paediatric malaria patients with initial parasite counts between 1,000 and 150,000 per µL. All participants received 30 mg/kg of oral fosmidomycin twice daily and 16 mg/kg of oral piperaquine once daily for 3 days.

After 28 days of follow-up, all 83 participants had adequate clinical and parasitological response (ACPR).  Two recorded treatment failures were identified as reinfections. Twelve late parasitological failures were reported but were identified as new infections. The resulting polymerase chain reaction-corrected ACPR rate at day 63 was 100 percent.

At day 7, all participants tested negative for malaria. The overall proportion of patients with gametocytes at days 0 and 7 were 5 and 3 percent, respectively. Rapid treatment response was reported in all participants.

Three adults and 49 children, who were anaemic at baseline, were observed to have increased haemoglobin levels 7 days after treatment. Five cases with baseline platelet counts of <100,000 mm3 showed normal levels by day 7. On the other hand, two patients experienced a reduction in haemoglobin level on day 3 but did not show any clinical consequences.

There was a total of 97 adverse events recorded, experienced by 55 patients. The majority of events were of the gastrointestinal tract and the upper and lower respiratory tract (24 percent for both). These were followed by skin lesions (13 percent), headaches and fevers (12 percent), anaemia (5 percent), and urogenital schistosomiasis infections (4 percent).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.